Drug co. executive gives pharma a sunny forecast

But medical device companies gets less love from health analysts.  

The Wall Street Journal: A Healthy Forecast For Pharma
Severin Schwan thinks the skeptics are wrong. Those who shun the pharmaceutical sector for its lack of prospects don't understand the potential created by a rapidly growing understanding of genetics and molecular biology, and the new drugs that will follow. ... the chief executive of Roche Holding AG, the world's seventh-largest drug firm by sales, is an informed optimist (Mijuk, 8/22).

Med City News/MinnPost: Medical Device Companies Get Scant Wall Street Love
On Monday, Morgan Stanley health analysts picked five healthcare stocks that they believe investors should own now. Notably, only one is a medical device firm. The stocks that they advised investors to buy now ... met key criteria that they were looking for - "clear fundamental growth trajectory, limited exposure to debt ceiling bill related spending cuts, attractive valuation and free cash flow yield and strong upside" to the analysts's price targets (Parmar, 8/19).